15.3% Above Target

MD's consensus price target is $23.2, -15.3% below the current price of $27.39. The 33 analysts tracking MD see downside risk at present valuations.

MD has a consensus rating of "Hold" based on 33 Wall Street analysts. The rating breakdown is mixed, with 17 Hold ratings making up the largest segment. The consensus 12-month price target of $23.2 implies -15.3% downside from current levels.

With a forward P/E of 11.9989x, MD trades at a relatively low valuation. The consensus target of $23.2 implies -15.3% move, suggesting the market may be pricing in risks.

The most bullish Wall Street analyst has a price target of $27 for MD, while the most conservative target is $19. The consensus of $23.2 represents the median expectation. Our quantitative valuation model projects a bull case target of $22 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

MD is heavily covered by Wall Street, with 33 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 17 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month MD stock forecast based on 33 Wall Street analysts shows a consensus price target of $23.2, with estimates ranging from $19 (bear case) to $27 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $17, with bear/bull scenarios of $11/$22.

Our quantitative valuation model calculates MD's fair value at $17 (base case), with a bear case of $11 and bull case of $22. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 42/100.

MD trades at a forward P/E ratio of 12.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 14.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Analysts are cautious on MD, with 2 Sell ratings and a price target of $23.2 (-15.3% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

MD analyst price targets range from $19 to $27, a 34% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $23.2 consensus represents the middle ground. Our model's $11-$22 range provides an independent fundamental perspective.